Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes

NCT01617135 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: CVT-301
DRUG: Placebo
DRUG: Sinemet (carbidopa/levodopa)
DRUG: CVT-301

Sponsor

Acorda Therapeutics

Collaborators

[object Object]